Genotypes for genetic polymorphisms in p53 and p21 and their effects on risk of CBP
| Genotype | Cases (%)* | Controls (%)* | OR (95% CI) | ORadj. (95% CI)† |
|---|---|---|---|---|
| P53 intron 3‡ | ||||
| WW | 280 (94.6) | 258 (92.8) | 1.00 | 1.00 |
| WM | 16 (5.4) | 20 (7.2) | 0.74 (0.37-1.45) | % (0.22-1.58) |
| MM | 0 (0.00) | 0 (0.0) | – | – |
| WM+MM | 16 (5.4) | 20 (7.2) | 0.74 (0.37-1.47) | % (0.22-1.58) |
| P53 C119G | ||||
| CC | 56 (18.7) | 51 (17.8) | 1.00 | 1.00 |
| CG | 144 (48.0) | 142 (49.5) | 0.92 (0.59-1.44) | 1.04 (0.58-1.87) |
| GG | 100 (33.3) | 94 (32.8) | 0.97 (0.60-1.55) | 0.87 (0.46-1.63) |
| CG+GG | 244 (81.3) | 236 (82.2) | 0.94 (0.62-1.43) | 0.97 (0.55-1.69) |
| P53 IVS6+62 G>A | ||||
| GG | 272 (89.8) | 265 (90.1) | 1.00 | 1.00 |
| GA | 31 (10.2) | 29 (9.9) | 1.04 (0.61-1.78) | 1.28 (0.63-2.57) |
| AA | 0 (0.00) | 0 (0.0) | – | – |
| GA+AA | 31 (10.2) | 29 (9.9) | 1.04 (0.61-1.78) | 1.28 (0.63-2.57) |
| P21 C98A | ||||
| CC | 100 (33.0) | 65 (22.5) | 1.00 | 1.00 |
| CA | 158 (52.2) | 173 (59.9) | 0.59 (0.41-0.87)§ | 0.48 (0.29-0.79)§ |
| AA | 45 (14.9) | 51 (17.6) | 0.57 (0.35-0.95)∥ | 0.67 (0.33-1.35) |
| CA+AA | 203 (67.0) | 224 (77.5) | 0.59 (0.41-0.85)§ | 0.51 (0.32-0.83)§ |
| P21 C70T | ||||
| CC | 66 (21.9) | 45 (15.4) | 1.00 | 1.00 |
| CT | 104 (34.6) | 107 (36.6) | 0.66 (0.42-1.06) | 0.56 (0.29-1.06) |
| TT | 131 (43.5) | 140 (48.0) | 0.64 (0.41-1.00)∥ | 0.51 (0.28-0.94)∥ |
| CT+TT | 235 (78.1) | 247 (84.6) | 0.65 (0.43-0.99)∥ | 0.53 (0.29-0.95)∥ |
↵* Data missing due to failure in DNA amplification.
↵† ORs were adjusted for potential confounders including gender, cigarette smoking, alcohol consumption, exposure duration, and intensity of benzene exposure.
↵‡ WW, wild-type homozygous; WM, wild-type/mutant heterozygous; MM, mutant homozygous.
↵§ P < 0.01.
↵∥ P < 0.05.